help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scheumman, G. F.
Right arrow Articles by Dralle, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheumman, G. F.
Right arrow Articles by Dralle, H.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 2168-2172, Copyright © 1995 by Endocrine Society


ARTICLES

Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas

GF Scheumman, C Hoang-Vu, Y Cetin, O Gimm, J Behrends, R von Wasielewski, A Georgii, W Birchmeier, A von Zur Muhlen and H Dralle
Department of Abdominal and Transplantation Surgery, Medizinische Hochschule Hannover, Germany.

The aim of this study was to evaluate the expression of E-cadherin as a potential marker for the prognosis of thyroid carcinomas. In normal thyroid (n = 8), the expression of E-cadherin messenger ribonucleic acid levels was uniformly high and seemed to be restricted to thyrocytes. Steady-state messenger ribonucleic acid levels and immunostaining were both completely lost in undifferentiated thyroid carcinomas (n = 7) and were variably reduced in differentiated thyroid carcinomas (n = 44). In a follow-up study during a mean of 4.5 +/- 1.4 yr, E-cadherin messenger ribonucleic acid and immunohistochemical expression were compared with the initial clinicopathological parameters and with locoregional recurrence and the development of nodal or distant metastases in differentiated thyroid carcinomas. Immunohistochemical expression of E-cadherin was greatly reduced with the progression to primary tumor stage 4 (pT4) tumors. In parallel, patients with pT4 tumors had a higher rate of locoregional tumor recurrence and distant metastasis than did the group of patients with pT1-3 tumors. In 5 of 29 patients with pT4 tumors, positive E-cadherin staining of more than 30% of the cells was detected. None of these patients showed signs of a regional recurrence or distant metastases during an observation period of 4.3 +/- 1.1 yr. In 13 patients with E- cadherin-positive tumors, none developed new distant metastases which was in contrast to 7 of the group of 31 patients with less than 30% E- cadherin-positive cells. Thus, E-cadherin expression seems to be associated with the dedifferentiation, progression, and metastatic spread of thyroid carcinomas and may be a useful marker for the prognosis of these tumors.


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
V. Vasko, A. V. Espinosa, W. Scouten, H. He, H. Auer, S. Liyanarachchi, A. Larin, V. Savchenko, G. L. Francis, A. de la Chapelle, et al.
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion
PNAS, February 20, 2007; 104(8): 2803 - 2808.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. D. Yang, E. R. Camp, F. Fan, L. Shen, M. J. Gray, W. Liu, R. Somcio, T. W. Bauer, Y. Wu, D. J. Hicklin, et al.
Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma Cells
Cancer Res., January 1, 2006; 66(1): 46 - 51.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
E. R. Camp, W. Liu, F. Fan, A. Yang, R. Somcio, and L. M. Ellis
RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis
Ann. Surg. Oncol., April 1, 2005; 12(4): 273 - 281.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Ishigaki, H. Namba, M. Nakashima, T. Nakayama, N. Mitsutake, T. Hayashi, S. Maeda, M. Ichinose, T. Kanematsu, and S. Yamashita
Aberrant Localization of {beta}-Catenin Correlates with Overexpression of Its Target Gene in Human Papillary Thyroid Cancer
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3433 - 3440.
[Abstract] [Full Text] [PDF]


Home page
INT J SURG PATHOLHome page
P. Smyth, O. Sheils, S. Finn, C. Martin, J. O'Leary, and E. C. Sweeney
Real-time Quantitative Analysis of E-cadherin Expression in ret/PTC-1-Activated Thyroid Neoplasms
International Journal of Surgical Pathology, October 1, 2001; 9(4): 265 - 272.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Böhm, L. Niskanen, K. Kiraly, J. Kellokoski, M. Eskelinen, S. Hollmen, E. Alhava, and V.-M. Kosma
Expression and Prognostic Value of {{alpha}}-, {beta}-, and {{gamma}}-Catenins in Differentiated Thyroid Carcinoma
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4806 - 4811.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
E. Pötter, C. Bergwitz, and G. Brabant
The Cadherin-Catenin System: Implications for Growth and Differentiation of Endocrine Tissues
Endocr. Rev., April 1, 1999; 20(2): 207 - 239.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society